Q4 2025 Puma Biotechnology Inc Earnings Call Transcript
Key Points
- Puma Biotechnology Inc (PBYI) reported a total revenue of $75.5 million for Q4 2025, showing an increase from previous quarters.
- Product revenue net for Q4 2025 was $59.9 million, up from $51.9 million in Q3 2025 and $54.4 million in Q4 2024.
- The company achieved positive net income for the full year 2025, marking the third consecutive year of profitability.
- Enrollment in the Alisa Breast 1 trial exceeded expectations, reaching 150 patients ahead of schedule.
- Puma Biotechnology Inc (PBYI) plans to initiate a second trial of alisertib in small cell lung cancer, indicating ongoing research and development efforts.
- New prescriptions for Nerlynx were down approximately 11.4% compared to Q3 2025.
- The company anticipates higher gross-to-net adjustments for 2026, driven by increased government chargebacks and Medicare/Medicaid share.
- SG&A expenses increased to $18.4 million in Q4 2025 from $16.8 million in Q3 2025.
- Research and development expenses are expected to increase by 30 to 35% year over year in 2026.
- Puma Biotechnology Inc (PBYI) reported a cash burn of approximately $3.1 million in Q4 2025, compared to $1.6 million in Q3 2025.
I better.
Right.
Good morning. Good afternoon, ladies and gentlemen.
My name is Sherry and I will be your conference call operator today. At this time, all participants are in a listen-only mode after the speaker's formal remarks, so it'll be a question-and-answer session. If you would like to ask a question during that time, simply press the key, then the number 1 on your telephone keypad. If you would like to withdraw your question, please press 2. If you should require operator assistance during the conference, please press 0 as a reminder, this call is being recorded. I would now like to turn the conference over to Marianne Mohanason, Senior Director of IR for Puma Biotechnology. You may begin your conference.
Thank you, Sherry. Good afternoon and welcome to PUMA's conference call to discuss our earnings results for the 4th quarter in full year 2025.
Joining me on the call today are Alan Auerbach, Chief Executive Officer, President and Chairman of the Board
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
